

Abstract

AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS

The present invention provides a prophylactic and/or
5 therapeutic agent for amyotrophic lateral sclerosis (ALS),
which contains one or more kinase inhibitors selected from the
group consisting of an epithelial cell growth factor receptor
(EGFR) inhibitor, a fibroblast growth factor receptor (FGFR)
inhibitor, an Aurorakinase inhibitor, a protein kinase A (PKA)
10 inhibitor, a protein kinase C (PKC) inhibitor, an MEK inhibitor,
an Met inhibitor, a JNK inhibitor, a Syk inhibitor and a JAK
inhibitor, a prostaglandin analogue and an estrogen receptor
antagonist, or one or more kinase inhibitors selected from the
group consisting of Tivozanib and an analog thereof, SB 216763,
15 Cdk2 Inhibitor II, BUDESONIDE, RIBOFLAVIN, alpha-TOCHOPHEROL,
AMODIAQUINE, SU9516, Sunitinib and an analog thereof, GSK-3
Inhibitor XIII, Bisindolylmaleimide I, HYDROQUINONE,
FLUNISOLIDE, MGCD-265, Indirubin-3'-monoxime, HYDRASTINE
(1R,9S), PIPERINE, BUTAMBEN, Axitinib and an analog thereof,
20 APOMORPHINE, FENBUFEN, Bosutinib (SKI-606) and an analog
thereof, a Weel Inhibitor, Cdk2 Inhibitor IV, NU6140, 3-
hydroxybutyric acid, AT9283, Imatinib, Nilotinib, Rebastinib,
and Bafetinib for the prophylaxis and/or treatment of ALS.
Particularly, using a compound already on the market as a
25 pharmaceutical product, a pharmaceutical product for the
prophylaxis or treatment of ALS can be developed rapidly at a
low cost.

(No drawing to be published)